PPARG and type 2 diabetes mellitus: Thiazolidinediones (TZD), a class of synthetic agonists of peroxisome proliferator-activated receptor gamma (PPARγ), initially used as insulin sensitizers for the treatment of type 2 diabetes, have been shown to affect cellular metabolism.